Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
BMY

BMY - Bristol-Myers Squibb Co Stock Price, Fair Value and News

41.42USD-0.06 (-0.14%)Delayed as of 14 Jun 2024, 03:45 pm ET

Market Summary

BMY
USD41.42-0.06
Delayedas of 14 Jun 2024, 03:45 pm
-0.14%

BMY Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

BMY Stock Price

View Fullscreen

BMY RSI Chart

BMY Valuation

Market Cap

84.0B

Price/Earnings (Trailing)

-11.7

Price/Sales (Trailing)

1.85

EV/EBITDA

30.92

Price/Free Cashflow

6.72

BMY Price/Sales (Trailing)

BMY Profitability

EBT Margin

-12.84%

Return on Equity

-43.56%

Return on Assets

-7.25%

Free Cashflow Yield

14.88%

BMY Fundamentals

BMY Revenue

Revenue (TTM)

45.5B

Rev. Growth (Yr)

4.66%

Rev. Growth (Qtr)

3.38%

BMY Earnings

Earnings (TTM)

-7.2B

Earnings Growth (Yr)

-626.57%

Earnings Growth (Qtr)

-525.93%

Breaking Down BMY Revenue

52 Week Range

40.8566.38
(Low)(High)

Last 7 days

1.4%

Last 30 days

-7.3%

Last 90 days

-20.8%

Trailing 12 Months

-35.4%

How does BMY drawdown profile look like?

BMY Financial Health

Current Ratio

1.11

Debt/Equity

3

Debt/Cashflow

0.28

BMY Investor Care

Dividend Yield

4.01%

Buy Backs (1Y)

3.51%

Diluted EPS (TTM)

-3.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202445.5B000
202345.8B45.2B44.9B45.0B
202247.0B47.1B46.7B46.2B
202142.8B44.4B45.5B46.4B
202031.0B34.9B39.4B42.5B
201923.3B23.9B24.2B26.1B
201821.0B21.6B22.0B22.6B
201720.0B20.2B20.6B20.8B
201616.9B17.6B18.5B19.4B
201516.1B16.4B16.5B16.6B
201416.4B16.2B16.1B15.9B
201316.2B15.8B16.1B16.4B
201221.5B20.5B18.9B17.6B
201119.7B20.4B20.9B21.2B
201019.3B19.4B19.4B19.5B
200917.1B16.6B16.1B18.8B
2008016.3B17.0B17.7B
200700015.6B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Bristol-Myers Squibb Co

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
shanahan karin
acquired
-
-
3,306
evp, glob. prod. dev. & supply
Apr 01, 2024
shanahan karin
sold (taxes)
-63,376
52.99
-1,196
evp, glob. prod. dev. & supply
Mar 10, 2024
hoch lynelle
acquired
-
-
4,351
president, cell therapy org.
Mar 10, 2024
elkins david v
acquired
-
-
64,326
evp, chief financial officer
Mar 10, 2024
hirawat samit
sold
-
-
-11,705
evp,chief med.offr.,drug dev.
Mar 10, 2024
caforio giovanni
sold
-
-
-57,536
executive chair of the board
Mar 10, 2024
hoch lynelle
sold (taxes)
-70,357
53.79
-1,308
president, cell therapy org.
Mar 10, 2024
plenge robert m
sold (taxes)
-105,697
53.79
-1,965
evp, chief research officer
Mar 10, 2024
gallman cari
sold (taxes)
-37,437
53.79
-696
evp, corporate affairs
Mar 10, 2024
leung sandra
sold (taxes)
-896,141
53.79
-16,660
evp, general counsel

1–10 of 50

Which funds bought or sold BMY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
94.92
87,950
219,375
0.02%
Jun 10, 2024
Hamilton Wealth, LLC
added
106
1,953,430
3,608,900
1.13%
Jun 07, 2024
Railway Pension Investments Ltd
unchanged
-
4,778,160
88,739,600
0.86%
Jun 06, 2024
WESTWOOD HOLDINGS GROUP INC
reduced
-44.29
-7,727,000
11,065,000
0.09%
Jun 04, 2024
DekaBank Deutsche Girozentrale
reduced
-1.41
6,147,000
209,494,000
0.39%
Jun 03, 2024
CACTI ASSET MANAGEMENT LLC
unchanged
-
-363,407
1,503,200
0.12%
May 30, 2024
CAMBRIDGE TRUST CO
reduced
-63.35
-11,262,800
7,121,970
0.27%
May 29, 2024
Garde Capital, Inc.
reduced
-11.04
-9,000
121,000
0.01%
May 29, 2024
Pathway Financial Advisers, LLC
new
-
59,906
59,906
0.02%
May 29, 2024
Clean Yield Group
unchanged
-
12,205
226,681
0.09%

1–10 of 49

Are Funds Buying or Selling BMY?

Are funds buying BMY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BMY
No. of Funds

Unveiling Bristol-Myers Squibb Co's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.74%
198,155,594
SC 13G/A
Jan 25, 2024
blackrock inc.
8.3%
168,098,227
SC 13G/A
Feb 09, 2023
vanguard group inc
9.54%
202,927,620
SC 13G/A
Feb 07, 2023
blackrock inc.
8.1%
172,720,377
SC 13G/A
Feb 09, 2022
vanguard group inc
9.00%
199,834,483
SC 13G/A
Feb 01, 2022
blackrock inc.
7.6%
169,226,706
SC 13G/A
Feb 10, 2021
vanguard group inc
8.82%
199,340,458
SC 13G/A
Jan 29, 2021
blackrock inc.
7.6%
172,464,804
SC 13G/A
Feb 12, 2020
vanguard group inc
8.32%
194,860,154
SC 13G/A
Feb 05, 2020
blackrock inc.
7.3%
171,343,446
SC 13G/A

Recent SEC filings of Bristol-Myers Squibb Co

View All Filings
Date Filed Form Type Document
May 09, 2024
8-K
Current Report
May 03, 2024
4
Insider Trading
Apr 25, 2024
10-Q
Quarterly Report
Apr 25, 2024
8-K
Current Report
Apr 22, 2024
DEFA14A
DEFA14A
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading
Apr 02, 2024
4
Insider Trading

Peers (Alternatives to Bristol-Myers Squibb Co)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.0B
85.6B
-3.94% -10.00%
9.1
4.09
5.68% 202.39%
327.6B
61.4B
0.54% 19.05%
142.08
5.34
6.11% -82.30%
160.0B
29.5B
-4.21% 34.20%
42.52
5.42
12.76% -52.47%
156.6B
35.0B
-2.61% -29.78%
134.79
4.47
-26.40% -92.03%
79.1B
27.4B
-6.10% -18.51%
163.34
2.88
1.51% -91.32%
19.5B
16.0B
1.81% 133.24%
-39.52
1.22
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.31% -21.88%
9.66
2.43
54.01% 364.56%
3.7B
4.6B
-9.61% -18.87%
-484.91
0.82
-0.06% 94.55%
2.3B
9.0B
-13.20% -15.57%
-4.97
0.25
10.01% -27.45%
2.0B
676.2M
-1.62% -15.25%
12.84
2.94
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-16.75% 6.10%
-3.83
1.81
24.65% 80.36%
22.8M
1.3M
-2.94% -47.62%
-3.08
17.54
-98.14% -104.71%
16.7M
89.6M
-19.67% -19.01%
-1.17
0.19
287.27% -129.41%
2.5M
21.5M
-5.26% -89.66%
-0.32
0.11
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Bristol-Myers Squibb Co News

Latest updates
MarketBeat2 minutes ago
Forbes01 May 202407:00 am

Bristol-Myers Squibb Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue3.4%11,86511,47710,96611,22611,33711,40611,21811,88711,64811,98511,62411,70311,07311,06810,54010,12910,7817,9456,0076,2735,920
Gross Profit--------------8,1588,0387,4307,1195,4534,2174,3014,096
Costs and Expenses138.5%23,3819,8038,8299,3678,5679,5479,0099,9299,96110,1279,46710,1508,54321,5198,2838,50211,0858,0744,6584,4973,941
  S&GA Expenses14.2%2,3672,0732,0031,9341,7622,2661,9301,7871,8312,3541,7881,8821,6662,7211,7061,6281,6061,7341,0551,0761,006
  R&D Expenses8.8%2,6952,4782,2422,2582,3212,5102,4182,3212,2602,5182,9802,4782,2192,6552,4992,5222,3722,0971,3781,3251,348
EBITDA Margin-78.2%0.09*0.40*0.41*0.41*0.41*0.39*0.39*0.38*0.38*0.40*0.14*0.15*0.15*0.08*0.31*0.26*0.22*----
Income Taxes545.5%392-88.00203-218503-166601529404-514605492501-4243791,707462931-17.00337264
Earnings Before Taxes-787.9%-11,5161,6742,1371,8592,7701,8592,2091,9581,6871,8582,1571,5532,530-10,4512,2571,627-304-1291,3491,7761,979
EBT Margin-168.5%-0.13*0.19*0.19*0.19*0.19*0.17*0.17*0.16*0.15*0.17*-0.09*-0.09*-0.09*-0.16*0.09*0.07*0.09*----
Net Income-525.9%-11,9112,7971,9284.002,2623,3651,6068.005.003,9171,546-6.00-8.00-10,0271,872-85.00-775-1,0561,3531,4321,710
Net Income Margin-201.6%-0.16*0.16*0.10*0.09*0.12*0.12*0.15*0.15*0.12*0.12*-0.19*-0.18*-0.19*-0.21*0.00*-0.02*0.03*----
Free Cashflow-35.0%2,5503,9224,4091,6282,6922,9603,4401,9893,5593,7374,9962,8503,6513,0722,1144,3623,751----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets4.1%99,03195,15991,26393,48994,28196,82098,196100,357103,034109,314110,893110,797112,435118,481125,536128,076129,285129,94457,43355,16334,834
  Current Assets-9.8%28,66931,77027,63228,07427,08627,27326,79630,18630,12133,26231,44329,16127,11130,19234,27734,34331,85329,35440,19137,71617,093
    Cash Equivalents-18.6%9,33011,4647,5148,3729,0489,3257,95710,96012,57914,31613,87911,39711,32114,97319,86020,36216,24612,82030,48928,4047,335
  Inventory12.1%2,9852,6622,4362,3642,6052,3392,0742,1422,1042,0952,1632,1371,9532,0741,9492,3842,8364,2931,1921,3081,283
  Net PPE1.6%6,7506,6466,4816,3556,2796,2556,0355,9706,0476,0495,8685,7955,7635,8865,7405,7776,1126,2524,8304,8494,985
  Goodwill2.7%21,73821,16921,14721,16321,16221,14921,11220,44620,50020,50220,51920,52920,52420,54720,51720,57822,45222,4886,5136,533-
Liabilities25.6%82,48365,67462,20161,45962,39565,70265,46267,69671,38973,30873,60973,92374,76280,59975,30678,91679,30878,24639,67939,01219,517
  Current Liabilities16.0%25,82222,26223,46220,15019,08521,89018,93020,91522,82121,86821,46018,99117,33019,08020,46423,42119,23218,30410,4899,7118,841
  Short Term Borrowings98.5%6,1903,119-------------------
  Long Term Debt35.0%49,48736,65332,13734,65635,07835,05636,96637,10737,45039,60539,67742,50344,50548,33644,61446,10646,10546,15024,39024,4335,635
    LT Debt, Non Current35.0%49,48736,65332,13734,65635,07835,05636,96637,10737,45039,60539,67742,50344,50548,33641,36441,85342,84443,38724,39024,4335,635
Shareholder's Equity-44.0%16,49029,43028,99857.0045,14025,50344,95629243,75660.0022,62566.0043,85260.0050,23049,16049,97743,70917,75416,15115,317
  Retained Earnings-45.6%15,64028,76628,21827,44926,56825,50324,67524,21723,94823,82022,62522,16822,20421,28132,41431,56532,67134,47436,55535,87035,109
  Additional Paid-In Capital-0.1%45,65545,68444,84945,29945,14045,16544,95644,37543,75644,36144,29244,06443,85244,32544,43544,44443,25443,7092,2062,1502,103
Shares Outstanding-------2,1262,1352,129-2,2202,2222,233-2,2602,2542,263-1,6291,6361,636
Minority Interest5.5%58.0055.0064.0057.0062.0057.0063.0061.0065.0060.0071.0066.0068.0060.0072.0066.0066.0010010610299.00
Float----133,499---164,301---148,383---132,443---74,102-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-33.3%2,8344,2524,7511,8872,9703,3063,6872,2613,8124,0575,2663,0603,8243,3552,2674,4933,9372,1812,5562,0831,390
  Share Based Compensation4.7%13312713213712211911511610713314215715117118521321028456.0048.0053.00
Cashflow From Investing-1357.5%-19,618-1,346-410-329-2101,213-2,081-28995.00401-976180-143-11,812-213556610-12,1794917151,060
Cashflow From Financing1414.4%14,644967-5,160-2,173-3,050-3,246-4,543-3,520-5,653-3,967-1,780-3,182-7,2953,483-2,587-993-1,054-7,677-94118,268-2,029
  Dividend Payments4.5%1,2121,1601,1911,1971,1961,1451,1541,1501,1851,0991,0901,0991,1081,0211,0161,0211,017668671671669
  Buy Backs---4,0009052502,416701-5,0002,7515251,2361,7751,465--81.007,000300--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BMY Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF EARNINGS - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total Revenues$ 11,865$ 11,337
Cost of products sold[1]2,9322,566
Marketing, selling and administrative2,3671,762
Research and development2,6952,321
Acquired IPRD12,94975
Amortization of acquired intangible assets2,3572,256
Other (income)/expense, net81(413)
Total Expenses23,3818,567
(Loss)/Earnings before income taxes(11,516)2,770
Income tax provision392503
Net (loss)/earnings(11,908)2,267
Noncontrolling interest35
Net (loss)/earnings attributable to BMS$ (11,911)$ 2,262
(Loss)/Earnings per common share:  
Basic (usd per share)$ (5.89)$ 1.08
Diluted (usd per share)$ (5.89)$ 1.07
Net product sales  
Total Revenues$ 11,559$ 11,048
Alliance and other revenues  
Total Revenues$ 306$ 289
[1]Excludes amortization of acquired intangible assets

BMY Balance Sheet

2024-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 9,330$ 11,464
Marketable debt securities340816
Receivables10,44710,921
Inventories2,9852,662
Other current assets5,5675,907
Total Current assets28,66931,770
Property, plant and equipment6,7506,646
Goodwill21,73821,169
Other intangible assets32,76027,072
Deferred income taxes2,7232,768
Marketable debt securities367364
Other non-current assets6,0245,370
Total Assets99,03195,159
Current liabilities:  
Short-term debt obligations6,1903,119
Accounts payable3,5393,259
Other current liabilities16,09315,884
Total Current liabilities25,82222,262
Deferred income taxes442338
Long-term debt49,48736,653
Other non-current liabilities6,7326,421
Total Liabilities82,48365,674
Commitments and Contingencies
BMS Shareholders’ equity:  
Preferred stock00
Common stock292292
Capital in excess of par value of stock45,65545,684
Accumulated other comprehensive loss(1,400)(1,546)
Retained earnings15,64028,766
Less cost of treasury stock(43,697)(43,766)
Total BMS Shareholders’ equity16,49029,430
Noncontrolling interest5855
Total Equity16,54829,485
Total Liabilities and Equity$ 99,031$ 95,159
BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
 CEO
 WEBSITEbms.com
 INDUSTRYPharmaceuticals
 EMPLOYEES34300

Bristol-Myers Squibb Co Frequently Asked Questions


What is the ticker symbol for Bristol-Myers Squibb Co? What does BMY stand for in stocks?

BMY is the stock ticker symbol of Bristol-Myers Squibb Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bristol-Myers Squibb Co (BMY)?

As of Thu Jun 13 2024, market cap of Bristol-Myers Squibb Co is 84.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BMY stock?

You can check BMY's fair value in chart for subscribers.

What is the fair value of BMY stock?

You can check BMY's fair value in chart for subscribers. The fair value of Bristol-Myers Squibb Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bristol-Myers Squibb Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BMY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bristol-Myers Squibb Co a good stock to buy?

The fair value guage provides a quick view whether BMY is over valued or under valued. Whether Bristol-Myers Squibb Co is cheap or expensive depends on the assumptions which impact Bristol-Myers Squibb Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMY.

What is Bristol-Myers Squibb Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, BMY's PE ratio (Price to Earnings) is -11.7 and Price to Sales (PS) ratio is 1.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bristol-Myers Squibb Co's stock?

In the past 10 years, Bristol-Myers Squibb Co has provided 0.011 (multiply by 100 for percentage) rate of return.